Intensity Therapeutics, Inc.
A clinical stage biotechnology company whose mission is to create safer and more efficacious cancer therapies.
Westport, United States
13 employees
Post Ipo Secondary
Total: $33.80M
Biopharma, Biotechnology +1
General Information
Get notified when Intensity Therapeutics, Inc. moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Intensity Therapeutics, Inc.
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biopharma
About Intensity Therapeutics, Inc.
Taxonomy: Cancer therapy, Immunotherapy, Drug formulation, Clinical-stage, Solid tumor cancers, Immune-based approach, Pharmaceuticals, Chemotherapy treatments, Intratumoral injection, Healthcare innovation, Clinical study, Adaptive immune response, Micro-metastases, Biopharmaceuticals
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Secondary | •••••• | - | 26 Mar 2024 | |
| Post-IPO Equity | •••••• | - | 29 Jun 2023 | |
| Series A | •••••• | 5 |
|
28 Jun 2016 |
| Venture Round | •••••• | - | 12 Jun 2015 | |
| Venture Round | •••••• | - | 11 Feb 2014 |
Intensity Therapeutics, Inc. Alternatives & Competitors
Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mechanisms of...
Pioneering tomorrow's treatments for solid tumors and degenerative diseases through state-of-the-art...
Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunot...
FAQ About Intensity Therapeutics, Inc.
Don't just browse. Track.
Signal Tracker monitors Intensity Therapeutics, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
